No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 18 of the 40 quarters in the window, leaving 22 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T11:55:27.103Z. Latest historical point 2026-03-03. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for ABVC BioPharma, Inc. (ABVC) stock was $0.98 as of Oct 5, 2026, 4:00 PM EDT, down 2.97% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -67.1% · 3-year avg +2.9%/yr · 5-year avg -46.3%/yr
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States.
Biotechnology · Fremont, CA
Next Earnings Date
Nov 16, 2026
41 days away
EPS Estimate
-0.40
Revenue Est.
$113257.00
Last Quarter Results
EPS
$-0.60
vs Estimate
$-0.50
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ABVC | $25.48M | $0.98 | -2.97% | -67.14% | -46.33% | -44.60% | N/A |
| 2ATOS | $24.44M | $2.45 | +4.70% | -83.69% | -44.50% | -39.47% | vs ABVC |
| 3ATYR | $28.43M | $0.29 | +0.97% | -62.41% | N/A | N/A | vs ABVC |
| 4AYTU | $21.90M | $2.04 | -1.45% | -6.80% | -48.14% | -68.87% | vs ABVC |
| 5ACTU | $20.93M | $0.87 | +6.83% | -87.34% | N/A | N/A | vs ABVC |
| 6CRVO | $30.65M | $3.31 | +9.60% | -61.36% | -38.25% | -53.96% | vs ABVC |
forward FY estimate
N/A
$0.00
vs Estimate
$113257.00
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$0.98
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.40 | $-0.40 | $-0.40 | 1 |
| Quarter ending Dec 2026 | $-0.40 | $-0.40 | $-0.40 | 1 |
| Quarter ending Mar 2027 | $-0.40 | $-0.40 | $-0.40 | 1 |
| Quarter ending Jun 2027 | $-1.25 | $-1.25 | $-1.25 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $1.30 | $1.30 | $1.30 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $113257.00 | $113257.00 | $113257.00 | 1 |
| Quarter ending Dec 2026 | $113257.00 | $113257.00 | $113257.00 | 1 |
| Quarter ending Mar 2027 | $144441.00 | $144441.00 | $144441.00 | 1 |
| Quarter ending Jun 2027 | $25917.00 | $25917.00 | $25917.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $35.28M | $35.28M | $35.28M | 1 |
